Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Biochemical Genetics Department, |
RCV005254948 | SCV005373488 | likely pathogenic | 3-Methylglutaconic aciduria | 2024-09-02 | criteria provided, single submitter | clinical testing | The NM_014263.4(YME1L1):c.1999C>G p.(Leu667Val) is a missense variant that replaces the highly conserved leucine at position 667 to valine within the C-terminal metalloprotease domain of the protein. This variant is absent from the gnomAD and other population databases (PM2_Moderate). The aggregated score (0.726) of in silico prediction tools, predicts a deleterious effect (PP3_Supporting). YME1L1 is an ATP-dependent metalloprotease embedded in the inner mitochondrial membrane and has an important role in regulating mitochondrial homeostasis and morphology. It is implicated in the processing of OPA1, a crucial mediator of mitochondrial fusion and in degradation of other mitochondrial proteins, such as lipid transfer proteins and components of protein translocases. Our in vitro functional studies on patient-derived fibroblasts provide evidence that the c.1999C>G p.(Leu667Val) variant results in impaired YME1L1 proteolytic activity, as revealed by the accumulation of PRELID1 and abnormal OPA1 processing as compared to control fibroblasts. Moreover, mitochondrial fragmentation was observed in patients’ fibroblasts (PS3_strong). This variant co-segregates with the disease (PP1_supporting). In summary, this variant meets the criteria to be classified as likely pathogenic, according to the recommendations of The American College of Medical Genetics and Genomics (ACMG). |